Fenoglio Carla, Boicelli Clodomiro Andrea, Ottone Massimo, Addario Concetta, Chiari Patrizia, Viale Maurizio
Dipartimento di Biologia Animale, Università di Pavia, 27100 Pavia, Italy.
Anticancer Drugs. 2002 Nov;13(10):1043-54. doi: 10.1097/00001813-200211000-00008.
Efforts have been made to reduce the undesirable side effects of cisplatin, mainly nephro- and neurotoxicity, but their reduction is usually accompanied by a concomitant inhibition of antitumor activity. The local anesthetic procaine hydrochloride (P.HCl) improves the therapeutic index of cisplatin not only by the reduction of its nephro- and hemotoxicity, but also by an increase of its antitumor activity. We therefore investigated the effects of a combined treatment of cisplatin and P.HCl on rat kidneys and compared this to kidneys from rats treated with a toxic dose of cisplatin or P.HCl alone. Treatment with a saline solution was used as control. Dehydrogenase activities [succinate dehydrogenase (SDH) and NADPH diaphorase reaction demonstrating nitric oxide synthase (NOS/NADPHd)] and phosphatase activities [K -nitrophenyl phosphatase (K pNPPase), alkaline phosphatase (AlPase) and acid phosphatase (AcPase)] were studied on cryostatic sections of kidneys from controls and treated rats. Evidence of heavy morphological damage and altered AlPase and AcPase activities induced by cisplatin were observed in the S3 segment of the proximal tubules. In addition, SDH and K pNPPase activities showed some changes in the distal tubule cells. The NOS/NADPHd activity in macula densa was drastically reduced. Combined treatment of cisplatin and P.HCl greatly attenuated morphological alterations of the rat kidney and reduced the changes in enzyme activities, except for NOS/NADPHd activity, compared to the cisplatin-treated group of animals. The study indicates that, in cisplatin-induced nephrotoxicity, a significant role is played by enzyme activities, in particular K pNPPase and NOS/NADPHd, and that P.HCl can mitigate the nephrotoxicity of cisplatin, possibly by influencing some enzyme activities involved in important renal metabolic pathways.
人们已努力减少顺铂的不良副作用,主要是肾毒性和神经毒性,但副作用的减少通常伴随着抗肿瘤活性的同时抑制。局部麻醉剂盐酸普鲁卡因(P.HCl)不仅通过降低顺铂的肾毒性和血液毒性,还通过增强其抗肿瘤活性来提高顺铂的治疗指数。因此,我们研究了顺铂与P.HCl联合治疗对大鼠肾脏的影响,并将其与单独用毒性剂量的顺铂或P.HCl治疗的大鼠肾脏进行比较。用盐溶液治疗作为对照。对对照组和治疗组大鼠肾脏的冷冻切片研究了脱氢酶活性[琥珀酸脱氢酶(SDH)和显示一氧化氮合酶的NADPH黄递酶反应(NOS/NADPHd)]和磷酸酶活性[对硝基苯磷酸酶(K pNPPase)、碱性磷酸酶(AlPase)和酸性磷酸酶(AcPase)]。在近端小管的S3段观察到顺铂诱导的严重形态损伤以及AlPase和AcPase活性改变。此外,SDH和K pNPPase活性在远端小管细胞中显示出一些变化。致密斑中的NOS/NADPHd活性急剧降低。与顺铂治疗组动物相比,顺铂与P.HCl联合治疗大大减轻了大鼠肾脏的形态改变,并减少了酶活性的变化,但NOS/NADPHd活性除外。该研究表明,在顺铂诱导的肾毒性中,酶活性,特别是K pNPPase和NOS/NADPHd发挥了重要作用,并且P.HCl可能通过影响参与重要肾脏代谢途径的一些酶活性来减轻顺铂的肾毒性。